Cowden syndrome is an inherited condition, which is characterized by multiple, noncancerous growths on various parts of the body. People with the syndrome usually have a large head, benign tumors of the hair follicle, and white papules with a smooth surface in the mouth. The major cause of the syndrome is still unknown, however, genetic factors are considered as a major factor for the market growth. Over 100 types of cancers have been identified. According to cancer research UK, in 2012, globally over 14.1 million of new cancer cases were registered, which is expected to increase continuously in the coming future. According to a study, it is observed that in 99% of the patients suffering from this syndrome shows various symptoms such as breast carcinoma, colorectal polyposis, conjunctival hamartoma, generalized hyperkeratosis, goiter, and others. Because of deteriorating lifestyle due to alcoholism and smoking, there is a continued rise in the incidence of cancer. The global Cowden syndrome market is majorly driven by the increasing prevalence of Cowden syndrome across the globe. Due to lack of treatment, governments of various countries have started supporting the manufacturers for research and development. Additionally, increasing government support for research & development, rising healthcare expenditure, and changing lifestyle have fuelled the market growth. Many types of treatment are available in the market, however, all the treatment show some or other side effects on the body. Side effects of the treatment and the high cost of the medicines may slow the growth of the market during the forecasted period.
The global Cowden syndrome market is expected to grow at a CAGR of 6.7% during the forecast period 2017-2023.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5096
- Pharmaceutical Companies
- Government and private research companies
- Research and Development (R&D) Companies
- Drug Manufacturers and Suppliers
- Medical Research Laboratories
The global Cowden syndrome market is segmented on the basis of site, treatment and end users.
On the basis of the site, the market is segmented into the breast, thyroid, endometrium (uterus), colorectal, kidney, skin (melanoma), and others.
On the basis of the treatment, the market is categorized into genetic testing, chemotherapy, surgery & radiation therapy, targeted therapy, hormone therapy, biologic therapy, and other. The chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents. The targeted therapy is sub-segmented with monoclonal antibodies and tyrosine kinase inhibitors. Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.
On the basis of end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.
The Americas dominate the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer. Additionally, high healthcare expenditure, well-developed technology, and strong government support for research & development have fuelled the growth of the Americas Cowden syndrome market. Presence of the leading players and increasing availability of funds in this region are likely to support the growth in the coming future.
Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific. Availability of the funds for research & development and strong government support have driven the market growth. The Asia Pacific is the fastest growing Cowden syndrome market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support. India and China are expected to lead the market in this region.
On the other hand, the Middle East & Africa hold the least share of the market due to limited availability of funds and availability of medical facilities, and poor political conditions in Africa. The Middle East holds the major share in the Middle East & Africa Cowden syndrome market. Kuwait, Qatar, Oman, and South Arabia holds the major share of the Middle East market. However, the African region is expecting a healthy growth due to the presence of a huge opportunity for the development of the market.
Key Players in Global Cowden Syndrome Market
Some of key the players in the market are Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), Bristol-Myers Squibb Company (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Spectrum Pharmaceuticals Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Immunomedics (U.S.), and Oncomed Pharmaceuticals (U.S.)
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/5096
Detailed Table of Contents:
Table Of Contents
1 Report Prologue
2 Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
3 Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/5096
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312